Arch Oncology
Signal active
Organization
Contact Information
Overview
Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers.
The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
About
Industries
Biotechnology, Medical, Therapeutics, Oncology
Founded
2006
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Arch Oncology headquartered in United States, North America, operates in the Biotechnology, Medical, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $20.0B in funding across 80 round(s). With a team of 11-50 employees, Arch Oncology is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Arch Oncology, raised $1.3M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
0
Lead Investors
0
Total Funding Amount
$250.4M
Details
3
Arch Oncology has raised a total of $250.4M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 50.0M | ||
| 2021 | Late Stage Venture | 105.0M | ||
| 2016 | Early Stage Venture | 86.0M |
Investors
Arch Oncology is funded by 33 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Arch Oncology | - | FUNDING ROUND - Arch Oncology | 86.0M |
| Cultivation Capital | - | FUNDING ROUND - Cultivation Capital | 86.0M |
| Arch Oncology | - | FUNDING ROUND - Arch Oncology | 8.1M |
| Cultivation Capital | - | FUNDING ROUND - Cultivation Capital | 8.1M |
Recent Activity
There is no recent news or activity for this profile.